EBE and EFPIA have financed a study to understand the benefits of personalized medicine to patients, society and healthcare systems.
A consultancy firm called Charles River Associates has conducted this study on behalf of the European Biopharmaceutical Enterprises (EBE) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The final report was published on July 6th.
The objectives of this analysis were to (1) characterize the benefits of personalized medicine to patients, society and healthcare systems; (2) identify barriers and enablers to the development and adoption of personalized medicine in Europe; and (3) propose policy recommendations for decision-makers to overcome these barriers and incentivize the development and adoption of personalized medicine in Europe. Most of the case-studies used for this report focused on oncology (i.e. non-small cell lung cancer, breast cancer, ovarian cancer, and melanoma).
The three (main) benefits identified are: delivering better treatment for patients, delivering benefits of healthcare systems and society, and more efficient development of new medicines. Based on these benefits, a series of policy recommendations are included in the report:
Although none of the policy recommendations refer to in silico medicine nor CM&S, emphasis is placed on the need for better data collection e.g. on diagnostic uptake, in relation to HTA (better alignment of data requirements to improve evidence development and facilitate the value assessment process), where CM&S has a clear added value.